Akcea starts Phase IIb of AKCEA-APOCIII-LRx in hypertriglyceridemia

Akcea Therapeutics Inc. (NASDAQ:AKCA) began a double-blind, placebo-controlled Phase IIb trial to evaluate four doses of AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) in 100

Read the full 207 word article

User Sign In